grant

Positive allosteric modulation of metabotropic glutamate receptor 5; a novel approach for the treatment of schizophrenia and cognitive disorders [ 2011 - 2015 ]

Also known as: Enhancement of glutamate signalling as a novel approach to treat schizophrenia and cognitive disorders

Funded by National Health and Medical Research Council
Managed by Monash University
Provided by   National Health and Medical Research Council

Research Grant

[Cite as https://purl.org/au-research/grants/nhmrc/1013709]

Researchers: Dr Karen Gregory (Principal investigator)

Brief description The metabotropic glutamate receptor subtype 5 (mGluR5) has emerged as an exciting new target for the treatment of schizophrenia and cognitive disorders. We will investigate novel drug-binding sites on these receptors with the aim to discover new therapeutics. These studies also aim to definitively characterize mGluR5 activity following treatment with novel compounds to improve our understanding of the normal function of these important receptors.

Funding Amount $AUD 348,428.08

Funding Scheme Early Career Fellowships

Notes CJ Martin Biomedical ECF

Click to explore relationships graph
Help

Related Organisations

Related People

Subjects
Basic Pharmacology | G protein-coupled receptors | Medical and Health Sciences | Pharmacology and Pharmaceutical Sciences | cognitive disorders | drug development | glutamate receptors | molecular pharmacology | psychiatric disorders | schizophrenia | schizophrenia and related disorders |
Identifiers
Viewed: [[ro.stat.viewed]]
Saved to MyRDA Save to MyRDA